N/A Completed N=30 Treatment

Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes

Source: ClinicalTrials.gov NCT00834626 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2012

Primary outcomePrimary: Percentage of Participants Having Remission of Type 2 Diabetes — 76.66 Percentage of Participants

Summary

Ileal interposition shifts a segment of ileum proximally to achieve maximal meal stimulated Glucagon-Like Peptide-1 secretion and coupled with a limited/complete sleeve gastrectomy (depending on the Body Mass Index), for Ghrelin reduction, helps in achieving good glycemic control in Type 2 Diabetes patients.

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants Having Remission of Type 2 Diabetes	76.66	—
SECONDARY Percentage of Participants Not Requiring Insulin	90	—
SECONDARY Percentage of Participants Showing Decrease in Requirement of Oral Anti-diabetic Agents	93	—
SECONDARY Percentage of Participants Achieving Remission in Hypertension	90	—

Eligibility Criteria

Inclusion Criteria

Type 2 Diabetes (as defined by American Diabetes Association criteria)of more than 1 year duration
Body Mass Index 21 - 55 kg/m^2
Poor glycemic control (HbA1c > 8%) despite maximal use of Oral Hypoglycemic Agents and Insulin; or good control(lower HbA1c) but requiring progressively higher drug doses.
Gives Informed Consent for the surgery
Postmeal C peptide > 1.0 ng/mL
Age 25 - 75 years
Stable weight for more than 3 months

Exclusion Criteria

Type 1 Diabetes
Postmeal C peptide < 1 ng/mL
Pregnancy
Significant nephropathy requiring dialysis
Coexisting systemic disease
Previous gastric or intestinal resection surgery
Obesity due to organic illness

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00834626). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.